Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Lung Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 141Radiotherapy 115Cetuximab 95Docetaxel 69Radiotherapy, Intensity-Modulated 55Carboplatin 47pembrolizumab 46Surveys and Questionnaires 46Paclitaxel 41Fluorouracil 39Radiation 29Blood Specimen Collection 27Drug Therapy 26Erlotinib Hydrochloride 23Nivolumab 21Surgical Procedures, Operative 17Standard of Care 16Magnetic Resonance Spectroscopy 16Radiosurgery 14Pemetrexed 14Gemcitabine 14Everolimus 13Celecoxib 13durvalumab 12Low-Level Light Therapy 12Immunohistochemistry 12Cyclophosphamide 12Capecitabine 12Amifostine 12Chemoradiotherapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Head and Neck Neoplasms × cyclopropapyrroloindole × Clear all
NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Phase 2/3 Recruiting
200 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡